• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

IL32/BAFF 轴支持淋巴瘤生态系统中的生存对话,并被 NIK 抑制所破坏。

The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition.

机构信息

Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France; L'Héma-NexT, i-Site NexT, Nantes, France; GDR3697 Micronit, CNRS.

Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes - France; L'Héma-NexT, i-Site NexT, Nantes, France; GDR3697 Micronit, CNRS; Service d'Hématologie Clinique, Unité d'Investigation Clinique, CHU, Nantes.

出版信息

Haematologica. 2022 Dec 1;107(12):2905-2917. doi: 10.3324/haematol.2021.279800.

DOI:10.3324/haematol.2021.279800
PMID:35263985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9713562/
Abstract

Aggressive B-cell malignancies, such as mantle cell lymphoma (MCL), are microenvironment-dependent tumors and a better understanding of the dialogs occurring in lymphoma-protective ecosystems will provide new perspectives to increase treatment efficiency. To identify novel molecular regulations, we performed a transcriptomic analysis based on the comparison of circulating MCL cells (n=77) versus MCL lymph nodes (n=107) together with RNA sequencing of malignant (n=8) versus normal B-cell (n=6) samples. This integrated analysis led to the discovery of microenvironment-dependent and tumor-specific secretion of interleukin-32 beta (IL32β), whose expression was confirmed in situ within MCL lymph nodes by multiplex immunohistochemistry. Using ex vivo models of primary MCL cells (n=23), we demonstrated that, through the secretion of IL32β, the tumor was able to polarize monocytes into specific MCL-associated macrophages, which in turn favor tumor survival. We highlighted that while IL32β-stimulated macrophages secreted several protumoral factors, they supported tumor survival through a soluble dialog, mostly driven by BAFF. Finally, we demonstrated the efficacy of selective NIK/alternative-NFkB inhibition to counteract microenvironment-dependent induction of IL32β and BAFF-dependent survival of MCL cells. These data uncovered the IL32β/BAFF axis as a previously undescribed pathway involved in lymphoma-associated macrophage polarization and tumor survival, which could be counteracted through selective NIK inhibition.

摘要

侵袭性 B 细胞恶性肿瘤,如套细胞淋巴瘤(MCL),是依赖于微环境的肿瘤,更好地理解淋巴瘤保护生态系统中的对话将为提高治疗效率提供新的视角。为了确定新的分子调控机制,我们对循环 MCL 细胞(n=77)与 MCL 淋巴结(n=107)进行了转录组分析,同时对恶性(n=8)与正常 B 细胞(n=6)进行了 RNA 测序。这种综合分析导致发现了白细胞介素 32β(IL32β)的微环境依赖性和肿瘤特异性分泌,其在 MCL 淋巴结内通过多重免疫组化原位得到了证实。通过原代 MCL 细胞(n=23)的体外模型,我们证明了肿瘤通过分泌 IL32β,能够将单核细胞极化为特定的与 MCL 相关的巨噬细胞,进而有利于肿瘤的存活。我们强调,虽然 IL32β 刺激的巨噬细胞分泌了几种促肿瘤因子,但它们通过可溶性对话支持肿瘤的存活,主要由 BAFF 驱动。最后,我们证明了选择性 NIK/替代-NFkB 抑制可以抵抗微环境依赖性的 IL32β诱导和 BAFF 依赖性的 MCL 细胞存活。这些数据揭示了 IL32β/BAFF 轴作为一个以前未被描述的途径,参与了淋巴瘤相关的巨噬细胞极化和肿瘤的存活,通过选择性 NIK 抑制可以抑制该途径。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/71e26128c92e/1072905.fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/a8f1b0377c22/1072905.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/4b6c91015c3f/1072905.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/13a57eb701cd/1072905.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/354d2141fb91/1072905.fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/a220107c8c26/1072905.fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/5a24e7430bd8/1072905.fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/0dc7a1b3a387/1072905.fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/71e26128c92e/1072905.fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/a8f1b0377c22/1072905.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/4b6c91015c3f/1072905.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/13a57eb701cd/1072905.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/354d2141fb91/1072905.fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/a220107c8c26/1072905.fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/5a24e7430bd8/1072905.fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/0dc7a1b3a387/1072905.fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3081/9713562/71e26128c92e/1072905.fig8.jpg

相似文献

1
The IL32/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition.IL32/BAFF 轴支持淋巴瘤生态系统中的生存对话,并被 NIK 抑制所破坏。
Haematologica. 2022 Dec 1;107(12):2905-2917. doi: 10.3324/haematol.2021.279800.
2
CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages.CSF1R 和 BTK 抑制作为破坏套细胞淋巴瘤和巨噬细胞之间对话的新策略。
Leukemia. 2019 Oct;33(10):2442-2453. doi: 10.1038/s41375-019-0463-3. Epub 2019 Apr 2.
3
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma.克服套细胞淋巴瘤微环境依赖性扩增的合理靶向治疗。
Blood. 2016 Dec 15;128(24):2808-2818. doi: 10.1182/blood-2016-06-720490. Epub 2016 Oct 3.
4
Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.药理学和基因组分析鉴定出针对套细胞淋巴瘤的 NF-κB 靶向治疗策略。
Nat Med. 2014 Jan;20(1):87-92. doi: 10.1038/nm.3435. Epub 2013 Dec 22.
5
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.序贯靶向布鲁顿酪氨酸激酶和Bcl-2以克服套细胞淋巴瘤中CD40诱导的ABT-199耐药性的生物学原理。
Oncotarget. 2015 Apr 20;6(11):8750-9. doi: 10.18632/oncotarget.3275.
6
NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells.NIK的过表达会增强信号,而其TRAF3结合结构域的缺失则会替代BAFF:BAFF-R介导的B细胞存活信号。
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10883-8. doi: 10.1073/pnas.0805186105. Epub 2008 Jul 28.
7
SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.SYK 抑制阻断了 BAFF- B 细胞受体的相互作用,从而拮抗了慢性淋巴细胞白血病中的 Mcl-1。
Haematologica. 2017 Nov;102(11):1890-1900. doi: 10.3324/haematol.2017.170571. Epub 2017 Aug 24.
8
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses.一种新型的基于患者的 3D 模型重现了套细胞淋巴瘤淋巴结的信号转导、免疫特征和体内伊布替尼反应。
Leukemia. 2023 Jun;37(6):1311-1323. doi: 10.1038/s41375-023-01885-1. Epub 2023 Apr 8.
9
BAFF receptor antibody for mantle cell lymphoma therapy.治疗套细胞淋巴瘤的 BAFF 受体抗体。
Oncoimmunology. 2021 Mar 5;10(1):1893501. doi: 10.1080/2162402X.2021.1893501.
10
Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma.Toll样受体1/2和5配体增强细胞周期蛋白D1和D3的表达并诱导套细胞淋巴瘤增殖。
PLoS One. 2016 Apr 28;11(4):e0153823. doi: 10.1371/journal.pone.0153823. eCollection 2016.

引用本文的文献

1
Targeting NF-kappaB-inducing kinase shapes B-cell homeostasis in myasthenia gravis.靶向核因子κB诱导激酶可塑造重症肌无力中的B细胞稳态。
J Neuroinflammation. 2025 Jan 24;22(1):17. doi: 10.1186/s12974-025-03342-5.
2
NIK Is a Mediator of Inflammation and Intimal Hyperplasia in Endothelial Denudation-Induced Vascular Injury.NIK 是血管内皮剥脱诱导的血管损伤中炎症和内膜增生的介质。
Int J Mol Sci. 2024 Oct 25;25(21):11473. doi: 10.3390/ijms252111473.
3
Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.

本文引用的文献

1
Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis.套细胞淋巴瘤将肿瘤相关巨噬细胞极化为M2样巨噬细胞,而M2样巨噬细胞反过来又促进肿瘤发生。
Blood Adv. 2021 Jul 27;5(14):2863-2878. doi: 10.1182/bloodadvances.2020003871.
2
The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.替代性 RelB NF-κB 亚基是弥漫性大 B 细胞淋巴瘤中的一个新型关键调控因子。
Blood. 2022 Jan 20;139(3):384-398. doi: 10.1182/blood.2020010039.
3
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors.
赋能巨噬细胞:肿瘤微环境中的癌症斗士——套细胞淋巴瘤。
Front Immunol. 2024 Mar 19;15:1373269. doi: 10.3389/fimmu.2024.1373269. eCollection 2024.
4
Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.套细胞淋巴瘤中的肿瘤微环境与基于免疫疗法的方法
Cancers (Basel). 2022 Jun 30;14(13):3229. doi: 10.3390/cancers14133229.
5
Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.颠覆平衡:走向理性的联合治疗以克服套细胞淋巴瘤中维奈托克的耐药性。
Leukemia. 2022 Sep;36(9):2165-2176. doi: 10.1038/s41375-022-01627-9. Epub 2022 Jun 20.
6
A BAFFling in mantle cell lymphoma.套细胞淋巴瘤中的一个难题。
Haematologica. 2022 Dec 1;107(12):2774-2775. doi: 10.3324/haematol.2022.280721.
CD163、PD-L1 和 FoxP3 阳性细胞浸润与既定风险因素无关,会对套细胞淋巴瘤患者的预后产生不利影响。
Br J Haematol. 2021 May;193(3):520-531. doi: 10.1111/bjh.17366. Epub 2021 Mar 8.
4
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.单细胞 RNA 测序揭示多发性骨髓瘤前体阶段免疫微环境受损。
Nat Cancer. 2020 May;1(5):493-506. doi: 10.1038/s43018-020-0053-3. Epub 2020 Apr 27.
5
Current Immunotherapy Approaches in Non-Hodgkin Lymphomas.非霍奇金淋巴瘤的当前免疫治疗方法
Vaccines (Basel). 2020 Nov 27;8(4):708. doi: 10.3390/vaccines8040708.
6
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.伊布替尼、奥滨尤妥珠单抗和维奈托克治疗复发和未经治疗的套细胞淋巴瘤患者:一项 1/2 期试验。
Blood. 2021 Feb 18;137(7):877-887. doi: 10.1182/blood.2020008727.
7
Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia.贝利尤单抗对B细胞活化因子(BAFF)的中和作用增强了慢性淋巴细胞白血病中的小分子抑制剂治疗效果。
Cancers (Basel). 2020 Sep 23;12(10):2725. doi: 10.3390/cancers12102725.
8
Molecular interactions and functions of IL-32.IL-32 的分子相互作用和功能。
J Leukoc Biol. 2021 Jan;109(1):143-159. doi: 10.1002/JLB.3MR0620-550R. Epub 2020 Sep 1.
9
The updated landscape of tumor microenvironment and drug repurposing.肿瘤微环境与药物再利用的更新景观。
Signal Transduct Target Ther. 2020 Aug 25;5(1):166. doi: 10.1038/s41392-020-00280-x.
10
Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.套细胞淋巴瘤的基因突变和特征:系统评价和荟萃分析。
Blood Adv. 2020 Jul 14;4(13):2927-2938. doi: 10.1182/bloodadvances.2019001350.